Phase 1 Results Support Development of TopiVert Therapy for Ulcerative Colitis

Phase 1 Results Support Development of TopiVert Therapy for Ulcerative Colitis
Positive safety data from a Phase 1 trial supports TopiVert’s continued development of TOP1288 to treat ulcerative colitis, the British pharma company announced. TOP1288 targets several important enzymes including P38, Src, Lck and Syk — all of which are involved in the underlying molecular process of inflammatory diseases. Preclinical studies have demonstrated that TOP1228 is effective in mice

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *